🔗 Share this article

As the US continues making historic changes to its vaccination guidelines, a particular individual appears unexpectedly: Dr. Tracy Beth Høeg, a US-based physician and public health researcher who first made her name by questioning COVID-19 vaccines during the pandemic and has focused upon potential fatalities after COVID-19 vaccination in her short time at the Food and Drug Administration.

Proposed Overhauls to Pediatric Vaccine Schedule

Public health authorities had intended to unveil sweeping changes to the pediatric vaccine schedule in December, aligning the US with the Danish vaccine program, sources say – a significant shift that would place the US out of step with a large portion of the international standard with little proof for improved outcomes. The planned update has been pushed back until the next year.

Rather than Vinay Prasad, Høeg is listed to present at the event. She was just designated temporary leader of the FDA’s drug evaluation center, the fifth appointee to lead the division this calendar year.

A Shift at the Regulatory Body

The acting appointment may indicate a closer partnership between the pharmaceutical and vaccine divisions as Dr. Høeg and Prasad consolidate power at the agency – and it points to a greater focus upon dismantling already-approved immunizations at the FDA.

The new acting director has repeatedly called for halting some childhood vaccine recommendations in the US in order to be more in line with Denmark's approach, a society with universal health coverage and a citizenry about the size of the state of Wisconsin.

So far statements, she has kept her attention on vaccines – typically the responsibility of Dr. Prasad, head of the FDA’s CBER – rather than medication approval.

Concerns Over Qualifications

The appointee has no obvious track record in medication creation, regulation or administrative roles, which has been standard for previous directors of the Center for Biologics Evaluation and Research. She has served at the FDA as a top consultant to the FDA chief and CBER since spring.

“She doesn’t seem to have any of the qualifications” for overseeing the drug-regulation department, stated Dr. Jonathan Howard. “She’s never run a clinical trial. She is not versed in managing a large organization. She lacks background in drug approvals.”

Former commissioners of CBER would “grasp laws and regulations and the research of pharmaceutical innovation”, commented a former acting FDA commissioner. “Objectively, she doesn’t have the kind of background that former directors who headed the center have had.”

This division has an vast workload at the FDA, the former commissioner emphasized.

“The public just zeroes in on the innovative therapies, but the generic program authorizes thousands of off-brand pharmaceuticals. There’s a biosimilars division, over-the-counter program and so forth, and each of these have to be managed,” she explained. “The thing you don’t keep your eye on, that’s the thing that I always told people is going to come back to haunt you.”

There is also, a major management component to the position, which oversees in excess of 5,000 personnel. “It is a massive management job, if you execute it properly,” Woodcock concluded.

Official Statement and Contentious Policies

In response to concerns about Dr. Høeg's fitness for the role and whether this assignment represents increased cooperation among regulatory chiefs on immunizations, a representative said that the “concerns stem from inaccurate presumptions”.

“This background matches the duties of her job,” the spokesperson said, pointing to the period Høeg spent advising the agency head on “drug safety and regulatory science, including predictive safety algorithms and shot safety tracking”.

As the temporary head, Dr. Høeg inherits the commissioner’s recently launched fast-track approval initiative, a controversial one-day drug-approval program that reportedly concerned her preceding directors. “How are these medications being chosen for this voucher program? Who is making the calls?” Howard questioned. “There’s a lot of lack of transparency going on at the regulatory body right now.”

Broadly speaking, he said, “the Food and Drug Administration looks to be trending towards laxer rules of pharmaceuticals, except for shots.”

Public Past Work on Immunizations

Regarding immunizations, Høeg has a more established, if troubling, history, some experts said. She authored a analysis using unconfirmed public submissions to determine the frequency of heart inflammation following COVID-19 vaccination. She counseled the state of Florida chief medical officer Dr. Joseph Ladapo, who was said to have changed statistics to imply COVID-19 vaccinations are pose a greater threat than they are.

Included in her “wish list” for the incoming federal leadership encompassed revising guidelines for novel immunizations and ending “unnecessary” vaccines, she stated after the election on a audio program. At the FDA, Dr. Høeg has according to sources proposed barring young men from receiving COVID-19 vaccinations.

“She’s an thorough true believer who commences with her beliefs and tailors the evidence to fit the data in a extremely deceptive, untruthful fashion,” Dr. Howard said.

Consolidating Power and a “Push for Payback”

Dr. Høeg aligned with fellow skeptics, {like|